SPOTLIGHT -
July 25th 2024
July 18th 2024
The behavioral and psychological symptoms of dementia contribute significantly to the greater rates morbidity and mortality among those with dementia.
July 2nd 2024
Kisunla (donanemab-azbt) is now approved by the FDA for adults with early symptomatic Alzheimer disease.
June 17th 2024
Review the multiple uses of metformin.
June 15th 2024
Here are highlights from the week in Psychiatric Times.
The Week in Review: July 3-7
From the FDA traditional approval of Leqembi to an examination of how we can improve mental health care for women of color, here are highlights from the week in Psychiatric Times.
Read More
FDA Grants Traditional Approval to Leqembi for the Treatment of Alzheimer Disease
Announcement follows the FDA’s accelerated approval and unanimous endorsement of the drug earlier this year.
The Week in Review: May 8-12
From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.
FDA Approves First Treatment for Agitation Associated With Alzheimer Disease Dementia
Brexpiprazole has been approved by the US Food and Drug Administration for the treatment of agitation associated with Alzheimer disease dementia.
The Week in Review: April 17-21
From eating disorders in entertainment to early intervention for schizophrenia, here are highlights from the week in Psychiatric Times.
Progress Made Toward the Approval of Treatment of Agitation Associated With Alzheimer Dementia
If approved, the drug will be the first FDA-approved treatment for agitation associated with Alzheimer dementia in the United States.
From the Pages of Psychiatric Times: March 2023
The experts weighed in on a wide variety of psychiatric issues for the March 2023 issue of Psychiatric Times.
The Week in Review: March 6-10
From Alzheimer disease treatments to the psychiatric implications of conspiracy theories, here are highlights from the week in Psychiatric Times.
The Clock-Drawing Test
A look at one of the most informative yet easy-to-administer tests for assessing brain dysfunction.
Lithium: A Narrative Overview and Future Frontiers
Lithium: what’s its history and where do we still need more information?
Alzheimer Disease: Are the Treatments Worse Than the Illness?
What are the available and upcoming AD treatments and how can you utilize them to best serve your patients?
From the Pages of Psychiatric Times: January 2023
The experts weighed in on a wide variety of psychiatric issues for the January 2023 issue of Psychiatric Times.
Is Alzheimer Disease Research Key to Effective Treatment of CTE in Athletes?
Alzheimer disease research may offer the key to effective treatment for former athletes.
The Week in Review: November 28-December 2
From evidence-based novel therapies for bipolar depression to potential indicators of early-stage Alzheimer disease, here are highlights from the week in Psychiatric Times.
Formic Acid as a Urinary Biomarker for Early-Stage Alzheimer Disease
New research finds that a urine test for formic acid could detect early-stage Alzheimer disease.
The Week in Review: November 7-11
From the cross-cultural dimensions of psychosis to the economic burden of schizophrenia, here are highlights from the week in Psychiatric Times.
Study Identifies Promising Potential Treatment for Alzheimer Disease
Results show comparisons between intranasal and intracerebroventricular distribution of an oxytocin derivative.
Treating Chronic Traumatic Encephalopathy in Athletes
Can Alzheimer disease research offer the key to effective treatment?
Caution Ahead: FDA Asks for More Info on Expanded Use of Antipsychotic Drug
Alzheimer disease psychosis treatment pimavanserin receives Complete Response Letter from the FDA.
Buyers Beware in Alzheimer Disease Neuroscience
Is our research about Alzheimer disease wrong?
Brain Inflammation May Link Alzheimer Disease With Sleep Disturbance
Study shows promising results for early detection and prevention efforts.
Phase 3 Study on Treatment of Agitation in Alzheimer Disease Doses First Patient
Top-line data for study is expected in late 2022, early 2023.
In Love: A Memoir of Love and Loss
Compelling new book discusses love, Alzheimer disease, and medical aid in dying.
Predicting Depression and Alzheimer Disease Through Major Depressive Disorder Risk Factors
Individuals with depression may be at a greater risk to develop late-onset Alzheimer disease, but a new study suggests depression onset may help predict Alzheimer disease.
The Science, Ethics, and Art of Disclosing a Dementia Diagnosis
How can you communicate the diagnosis in a way that relieves suffering and helps patients and their caregivers prepare for the future?
The First and Only Transdermal Patch for Alzheimer Disease
This donepezil transdermal system helps with the treatment on mild, moderate, or severe dementia of the Alzheimer type.
Study Links Lithium With Lower Risk of Dementia
Research also finds surprising results in patients with bipolar affective disorder.
Aducanumab: A Tentative Position
The American Academy of Neurology issued a position statement for mental health professionals, warning them to carefully discuss the benefits and known harms of aducanumab.
Do Amyloid Plaques Cause Alzheimer Disease?
A new study finds amyloid plaques accelerate the breakup of neurotransmitters, worsening neurodegenerative diseases like Alzheimer disease.
Moving Forward: Alzheimer Treatment Granted Breakthrough Therapy Designation
More potential good news for treating Alzheimer disease, as an 18-month open-label extension for lecanemab allows for its breakthrough status.